Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours.

ABSTRACT: The DNA damage response (DDR) maintains the stability of a genome faced with genotoxic insults (exogenous or endogenous), and aberrations of the DDR are a hallmark of cancer cells. These cancer-specific DDR defects present new therapeutic opportunities, and different compounds that inhibit key components of DDR have been approved for clinical use or are in various stages of clinical trials. Although the therapeutic rationale of these DDR-targeted agents initially focused on their action against tumour cells themselves, these agents might also impact the crosstalk between tumour cells and the immune system, which can facilitate or impede tumour progression. In this review, we summarise recent data on how DDR-targeted agents can affect the interactions between tumour cells and the components

SUBMITTER: Lutfi N 

PROVIDER: S-EPMC8656491 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature